11/20
08:06 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/7
04:11 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/28
01:16 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/7
10:56 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
10/7
10:56 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
10/7
08:10 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $70.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $70.00 price target on the stock.
9/30
06:38 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
9/30
06:38 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
9/30
06:38 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
9/27
07:41 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
9/27
07:41 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
9/27
07:35 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.
9/27
05:44 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
9/27
05:44 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
9/26
08:17 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
High
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/25
12:21 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
High
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
9/25
12:21 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
High
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
9/25
12:04 pm
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
9/25
12:04 pm
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
9/20
12:11 pm
cldx
Rating for CLDX
Low
Report
Rating for CLDX
9/18
09:17 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
9/16
12:11 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
9/16
11:34 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
9/9
12:14 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
9/9
11:33 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX